“…The efficacy and potential pharmacological mechanisms of KXS against AD were evaluated and proven to involve multiple targets, multi components and multiple pathways ( Luo et al, 2020 ; Yi et al, 2020 ). KXS improved cognitive function via regulating SIRT3-mediated neuronal cell apoptosis ( Su et al, 2023 ), activating the Wnt/beta-catenin signaling pathway in APP/PS1 mice and AD rats ( Shan et al, 2023 ; Xu et al, 2023 ). Network pharmacology analysis validated the multi-component and multi-target therapeutic mechanisms of KXS for treatment of AD, involving inhibiting Tau protein hyperphosphorylation, inflammation, and apoptosis ( Jiao et al, 2022 ; Wang et al, 2023 ).…”